echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lancet Oncol: Safety of low-dose, short-course radiotherapy before surgery for soft tissue sarcoma

    Lancet Oncol: Safety of low-dose, short-course radiotherapy before surgery for soft tissue sarcoma

    • Last Update: 2022-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Soft tissue sarcoma is a malignant tumor derived from fat, fascia, muscle, fiber, lymph and blood vessels, with different histological and biological characteristics, and different soft tissue sarcomas have different
    local infiltration, hematogenous and lymphatic metastasis tendencies.
    The incidence is higher in the elderly, and there is no sex difference
    Soft tissue sarcomas can occur anywhere, and about 75% of lesions are located on the extremities (most commonly in the thighs).

    The standard preoperative radiotherapy regimen for soft tissue sarcoma is 50 Gy divided into 25 sessions for 5 weeks and provides good local control, but major wound complications
    occur in about 35% of patients.
    The aim of the study was to assess the safety
    of moderately low fractionation, shorter course of radiotherapy.

    This is a single-center, open-label, single-arm Phase 2 trial that enrolled patients aged 18 years and older with non-metastatic soft tissue sarcoma and preoperatively received a total dose of 42.
    75 Gy (2.
    85 Gy daily in 15 divided doses for 3 weeks).

    The primary endpoint was the occurrence of major wound complications within 120 days of

    From December 18, 2018 to January 6, 2021, a total of 157 patients were screened, of whom 120 were enrolled in hypofractionated preoperative radiotherapy
    The median postoperative follow-up was 24 months (IQR 17-30).

    Of the 120 patients, 37 (31%) developed major wound complications
    at a median postoperative follow-up of 37 days.
    No patients experienced grade 3 or greater radiotherapy toxicity or treatment-related serious adverse effects
    during or within 4 weeks after the end of radiotherapy.
    Four of the 115 patients (3%) experienced at least grade 3 late radiation toxicity (after 6 months postoperatively): femoral fracture (n=2), lymphedema (n=1), skin ulceration (n=1).

    There were no treatment-related deaths

    In conclusion, hypofractionated radiotherapy for patients with soft tissue sarcoma before surgery is safe, more convenient for patients, or can replace conventional fractionated radiotherapy

    Original source:

    B Ashleigh Guadagnolo, et al.
    Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial.
    The Lancet Oncology.
    November 04, 2022.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.